The 8 most recent market catalysts affecting $NVCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 75
NeoVolta shares are trading lower after the company filed a prospectus for up to a $200 million mixed securities shelf offering.
This headline indicates a significant corporate action by NeoVolta. A 'mixed securities shelf offering' allows the company to issue various types of securities (e.g., common stock,…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
NeoVolta's NeoVolta Power Announces About $53M Binding Capacity Reservation Agreement With Infinite Grid Capital For Battery Storage Equipment For Northern Ontario Edge AI Data Center Projects In 2027
This $53 million binding agreement is a strong positive for NeoVolta, providing revenue visibility and validating its technology for large-scale industrial applications. It undersc…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
NeoVolta shares are trading higher after the company announced that its majority-owned subsidiary, NeoVolta Power, has entered into a five-year strategic supply and manufacturing collaboration with SK On.
This headline represents a significant corporate catalyst for NeoVolta (NVCT). The five-year strategic supply and manufacturing collaboration with SK On, a major player in the batt…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating
Cantor Fitzgerald analyst Pete Stavropoulos has initiated coverage on Nuvectis Pharma (NVCT) with an Overweight rating. This is a significant event for a smaller biotechnology comp…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
Nuvectis Pharma Files Base Prospectus Related To The Offer And Sale Of Up To $200M Of Securities
Nuvectis Pharma filed a base prospectus, allowing them to offer and sell up to $200 million in securities. This is a standard regulatory step for companies looking to raise capital…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
Nuvectis Pharma shares are trading lower after the comapny reported worse-than-expected Q2 EPS results.
This headline indicates a direct negative corporate catalyst for Nuvectis Pharma. Worse-than-expected earnings per share (EPS) often signal missed revenue targets, higher-than-anti…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
CORRECTION: Nuvectis Pharma Reported Q2 Financial Results On Aug. 4
The correction of Q2 financial results for Nuvectis Pharma (NVCT) is a moderate corporate catalyst. While earnings reports are always market-moving, a correction implies that the i…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate
Nuvectis Pharma announced its Q2 earnings, reporting a loss of $(0.30) per share, which was 15.38% worse than the analyst consensus of $(0.26). This earnings miss signals that the …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.